The CODA Study

Summary

Obesity and depression often co-occur, with roughly 30% of individuals with obesity also having a diagnosis of depression. One suggested mechanism behind this co-occurrence is “hyperactivity” of the immune system. Recent research has shown that the co-occurrence of depression and obesity in an individual increases the risk of heightened inflammation. Increased inflammation has also been shown in the brain in people with depression. Scientists have found that neuroinflammation (inflammation in the brain) impacts brain structure in people with both depression and people with obesity, which can impact their learning and memory.

The aim of this study is to investigate the feasibility of whether individuals with both obesity and depression will complete an 8-week course of minocycline, an antibiotic with anti-inflammatory properties, alongside their regular anti-depressant medication. Please note, minocycline contains gelatine. Likewise, we want to understand if participants are able to complete blood and saliva sample measurements, undergo 2 brain scans (optional), and complete interviews and questionnaires over the course of 5 visits (12 weeks total).